1. Introduction {#sec1}
===============

Irritable bowel syndrome (IBS) is a disease with a high incidence rate, and diarrhoea-predominant irritable bowel syndrome (IBS-D) is a subtype of irritable bowel syndrome with a major clinical manifestation. IBS has a prevalence ranging from 1.1 to 29.2% in the whole population according to the Rome III criteria, with the diarrhoea-predominant type accounting for about 23.4% \[[@B1], [@B2]\]. Diarrhoea-predominant irritable bowel syndrome (IBS-D) leads to a great deal of trouble \[[@B3]\]. However, the pathogenesis of diarrhoea-predominant irritable bowel syndrome is not yet clear, and its aetiology is complex and may be caused by a variety of factors including visceral allergies, inflammatory responses, heredity, gastrointestinal motility disorders, intestinal infections, and psychosocial factors. In addition, there is a lack of morphological or biochemical abnormalities and other available organic diseases to explain the clinical symptoms \[[@B4], [@B5]\]. The current treatment methods for IBS-D include drugs and acupuncture treatment; common drugs include pinaverium bromide, eluxadoline, alosetron, ramosetron, rifaximin, and intestinal probiotics. Currently, increasing studies have shown that acupuncture may have some effect on IBS-D, but there are no efficacy comparisons between acupuncture and commonly used oral drugs, and each patient uses different acupuncture points, so we were interested in conducting a systematic review to resolve these two problems.

Now, more and more studies use sham acupuncture as the control of acupuncture. However, there is a debate on whether sham acupuncture has curative effect and to what extent sham acupuncture does affect the final result; this question could be solved with the Network Meta-Analysis.

In this study, by collecting previously published treatments of IBS-D in randomized controlled treatment studies using acupuncture and oral common drugs, we expected to determine the following issues: (1) a ranking of acupuncture and drugs in the treatment of diarrhoea-predominant irritable bowel syndrome; (2) a ranking of acupuncture and drugs in their side effects on diarrhoea-predominant irritable bowel syndrome; (3) the extent to which sham acupuncture does effect the final result; (4) the acupoint distributions used to treat diarrhoea-predominant irritable bowel syndrome.

2. Materials and Method {#sec2}
=======================

We conducted a standardized report based on the preferred reporting items of the PRISMA statement \[[@B6], [@B7]\].

2.1. Research Methods {#sec2.1}
---------------------

We searched PubMed, the Cochrane Library, Embase, and 4 Chinese databases \[China National Knowledge Infrastructure (CNKI), Wanfang Database, VIP Database, and Chinese Biomedical Database (CBM)\] to conduct a comprehensive database retrieval using a (acupuncture or electro-acupuncture Or acupuncture, Sham Acupuncture, pinaverium bromide, alosetron, eluxadoline, ramosetron, rifaximin), (randomized controlled trials or randomized controlled trials or clinical trials), and (IBS-D) strategy (the retrieval time was from the building of database to 17^th^ October, 2017). In addition, the same search was conducted for the reference reviews and meta-analyses cited in manual searches, with no language restrictions set (searching strategy in [Supplementary 1](#supplementary-material-1){ref-type="supplementary-material"}).

2.2. Inclusion and Exclusion Criteria {#sec2.2}
-------------------------------------

We included randomized controlled trials that met the following eligibility criteria: (i) adult patients; (ii) single drug use; (iii) clinical trials with treatment duration greater than two weeks; (iv) articles that were not comments or commentary; and (v) patients that did not suffer from pregnancy or lactation, peptic ulcer, rectal disease, or liver or other systemic disease and had no previous history of gastroduodenal surgery or brain disease or surgery.

2.3. Research Options {#sec2.3}
---------------------

Articles were independently screened by two researchers. Initially, NoteExpress software (Beijing Aegean Sea Music Technology Co., Ltd.) was used to delete duplicate records. The remaining summaries and full texts were reviewed on the basis of inclusion and exclusion criteria, and disagreements were resolved through discussion.

2.4. Data Extraction and Quality Assessment {#sec2.4}
-------------------------------------------

Two reviewers (Lingping Zhu and Shasha Ye) independently extracted the relevant information from each eligible study based on a pre-prepared data abstraction sheet. Data included the location and study design of the trials, clinical characteristics, number of patients, patient age, diagnostic methods, treatment duration, outcome data, and side effects. The quality of the included studies was assessed using the Jadad scale, including three items such as randomized (2 points), double-blinded (2 points), and withdrawals and drop-outs (1 point) \[[@B8]\]. A Jadad score of 3 or higher was considered to be high quality. Disagreements were resolved by discussion.

The primary outcome was the number of people who showed effective treatment, with secondary outcomes including side effects and common acupuncture points. Common side effects included constipation and rash.

2.5. Data Synthesis and Analysis {#sec2.5}
--------------------------------

The assessments of acupuncture and drug efficacy were based on a combination of the data extracted from the included trials, and then direct and indirect comparisons were used to assess the overall effect of acupuncture and medications. In this meta-analysis of the network, we used a random-effects model in a Bayesian framework. The odds ratio (OR) and 95 % confidence interval (CI) were used to analyse the effects of acupuncture and drugs on the efficacy of diarrhoea-predominant irritable bowel syndrome. CIs with OR\> 1.0 indicated high risk, and CIs not containing 1.0 were considered statistically significant. All analyses used the GeMTC package generated by R software \[[@B9], [@B10]\].

Node-splitting models were used to assess the consistency of the meta-analysis of the network to test whether the results of the direct and indirect comparisons were consistent within the treatment cycle \[[@B23]\]. In the absence of direct or indirect comparison results, the node-split model cannot be executed. Therefore, we use heterogeneity analysis to quantify the degree of heterogeneity of I^2^ calculations. I^2^ \> 50 % of the value was considered heterogeneous throughout the experiment. To verify the robustness of the results, sensitivity analyses were performed by examining heterogeneity in each study and then recalculating the overall effect to see if any of the factors could affect the overall effect.

A mesh diagram, contribution graphs, and publication bias tests were drawn using STATA 14.0 software (Stata Corporation, College Station, TX, USA).

3. Results {#sec3}
==========

3.1. Included Research Features {#sec3.1}
-------------------------------

A total of 1119 articles were obtained from the system search. After reviewing the literature, 40 duplicates were deleted. In addition, due to discrepancies in inclusion criteria, 1046 articles were excluded. Finally, a total of 33 trials were identified ([Figure 1](#fig1){ref-type="fig"}) and are listed in [Table 1](#tab1){ref-type="table"} \[[@B23]--[@B40]\].

In total, 9712 patients diagnosed with IBS-D/IBS were enrolled in the assessed studies, mean age was between 38 and 46 years, the diagnosis criteria included clinical criteria, ROME I-III, and the treatment duration was from 2 weeks to 48 weeks, mainly between 4 and 12 weeks. The following seven therapeutic methods were included: A: acupuncture; B: eluxadoline; C: pinaverium bromide; D: alosetron; E: ramosetron; F: rifaximin; and G: sham acupuncture; H: placebo (vitamin C, etc.). Documents included 10 articles from China, 9 articles from the United States, 2 papers from France, 2 papers from Canada, 1 paper from United Kingdom, 5 articles from Japan, 1 article from Korea, and 3 articles from multicentre locations. Using the Jadad scale assessment, the overall Jadad score for study quality ranged from 1 to 7, and the median Jadad score was 4 (see [Table 1](#tab1){ref-type="table"} for details).

3.2. Routine Paired Meta-Analysis {#sec3.2}
---------------------------------

Compared with placebo, acupuncture significantly improved the symptoms of diarrhoea-predominant irritable bowel syndrome (OR: 7.7, 95% CI: 3.8-16.0, I^2^ = 0%) ([Figure 2](#fig2){ref-type="fig"}); compared with placebo, sham acupuncture significantly improved the symptoms of diarrhoea-predominant irritable bowel syndrome (OR:4.7, 95% CI: 2.0 to 11.0); compared with placebo, pinaverium bromide significantly improved the symptoms of diarrhoea-predominant irritable bowel syndrome (OR: 2.6, 95% CI: 1.5 to 4.1, I^2^ = 0%) ([Figure 2](#fig2){ref-type="fig"}); eluxadoline significantly improved the symptoms of diarrhoea-predominant irritable bowel syndrome compared with placebo (OR: 2.0, 95% CI: 1.4-2.8, I^2^ = 5.3%) ([Figure 2](#fig2){ref-type="fig"}); compared with placebo, alosetron also improved the symptoms of diarrhoea-predominant irritable bowel syndrome (OR: 2.0, 95% CI: 1.5-2.6, I^2^ = 53.3%); compared with placebo, ramosetron also improved the symptoms of diarrhoea-predominant irritable bowel syndrome (OR: 1.9, 95% CI: 1.5-2.4, I^2^ = 68.1%); and compared with placebo, rifaximin treatment improved the symptoms of diarrhoea-predominant irritable bowel syndrome (OR: 1.5, 95% CI: 1.0-2.0, I^2^ = 0%) ([Figure 2](#fig2){ref-type="fig"}). The efficacy of drugs compared with acupuncture and sham acupuncture was poor ([Figure 2](#fig2){ref-type="fig"}).

3.3. The Cumulative Probability Ranking {#sec3.3}
---------------------------------------

The cumulative probability ranking of the results for diarrhoea-predominant irritable bowel syndrome patients is as follows: acupuncture, sham acupuncture, pinaverium, alosetron = eluxadoline, ramosetron, and rifaximin. The probability distribution rankings of eluxadoline were equal, so we chose the probability of the closest top rank as its ranking result. The efficacy of acupuncture was much higher than that of other drugs (P = 0.977), while sham acupuncture had a higher drug efficacy (P = 0.90) than pinaverium bromide (P=0.69), alosetron (P = 0.35), eluxadoline (P= 0.30), ramosetron (P=0.31), and rifaximin (P=0.81) ([Figure 3](#fig3){ref-type="fig"}, [Table 2](#tab2){ref-type="table"}).

There were 22 studies that reported side effect data ([Table 1](#tab1){ref-type="table"}); there were no reported side effects from acupuncture, so acupuncture was not included in the analysis. The rest of the reported side effect data contained all other 6 treatment regimens ([Table 3](#tab3){ref-type="table"}). Because the side effects of acupuncture were 0, its side effects were the lowest, followed by other drugs; the smallest side effects were for eluxadoline (P = 0.39) and pinaverium bromide (P = 0.21), and there were more side effects from rifaximin (P = 0.44) than from other drugs. Ramosetron also showed more side effects than alosetron ([Figure 4](#fig4){ref-type="fig"}).

3.4. Network Plot {#sec3.4}
-----------------

We compared all of the included studies and drew network diagrams, with the studies incorporated into quality-based displays on a network map ([Figure 5](#fig5){ref-type="fig"}).

3.5. Acupuncture Preference Points {#sec3.5}
----------------------------------

In view of the different acupuncture points selected for each study, we selected the most commonly used acupoints, including ST-25, ST-37, ST-36, SP-6, GV-20, and EX-HN3; the use of these 6 acupoints was 4 times more common than other acupoints ([Table 4](#tab4){ref-type="table"}).

3.6. Brooks-Gelman-Rubin Diagnostic Plot, Density Plot, Node-Splitting Plot, and Cumulative Contribution Plot {#sec3.6}
-------------------------------------------------------------------------------------------------------------

By performing 20,000 convergence iterations, we obtained a Brooks-Gelman-Rubin diagnostic plot, and the track density map was acceptable; based on the node-splitting model, we found all studies in the region beneath the 4th line. We also obtained a cumulative contribution map from the STATA software (Figures [6](#fig6){ref-type="fig"}, [7](#fig7){ref-type="fig"}, [8](#fig8){ref-type="fig"}, and [9](#fig9){ref-type="fig"}).

3.7. Heterogeneity and Sensitivity Analysis {#sec3.7}
-------------------------------------------

Using heterogeneity analysis, we found that alosetron and ramosetron had significant heterogeneity; based on the sensitivity analysis, we corrected the OR for alosetron (OR: 1.29, 95% CI: 1.17-1.42) and the OR for placebo and ramosetron (OR: 1.33, 95% CI: 1.22-1.39), and no large directional change occurred even after corrections ([Figure 10](#fig10){ref-type="fig"}).

3.8. Publication Bias {#sec3.8}
---------------------

The funnel plot shows that all included studies were compared on a pairwise basis, and all the studies were found to be essentially symmetrical, indicating a small publication bias ([Figure 11](#fig11){ref-type="fig"}).

4. Discussion {#sec4}
=============

Through NMA, this article found that the effect of acupuncture treatment on diarrhoea-predominant irritable bowel syndrome was better than that of the assessed drugs, with close to no side effects. Previous studies have shown that the effects of acupuncture treatment on diarrhoea-predominant irritable bowel syndrome are still not yet clear, but there are several relevant studies to prove its possible role in treatment. Several studies have confirmed the co-occurrence of IBS and the excessive release of proinflammatory cytokines and insufficiencies in anti-inflammatory cytokine secretion \[[@B41]\]. Animal studies have shown that electroacupuncture can significantly reduce the peripheral blood flow of patients with 5-HT positive reactant content and reduce the sensitivity of afferent nerves, thereby reducing visceral hypersensitivity \[[@B42]\]. Studies also indicate that acupuncture can significantly reduce rat colon and dorsal root ganglia 5-HT concentrations \[[@B43]\]. Animal experiments have shown that acupuncture may serve as an effective treatment by regulating the abnormal state of colon mast cells \[[@B44]\]. Previous studies have also shown that acupuncture can reduce the number of mast EA cells in ovalbumin-sensitized mice, increasing visceral sensory thresholds and improving visceral hypersensitivity \[[@B45]\]. In addition, acupuncture can relieve thalamic pain in patients with advanced and central signalling pathways involving 5-HT \[[@B46]\]. At the same time, studies have shown that acupuncture has low side effects, an idea that has reached a certain consensus \[[@B47]\].

However, previous meta-analyses showed no significant benefit of acupuncture compared with sham acupuncture groups in the treatment of IBS. Only a few studies from China have demonstrated the superiority of acupuncture relative to drugs \[[@B48]\]. Other studies have shown that acupuncture is not or only slightly superior to sham acupuncture treatment \[[@B37]\]. However, our study only selected patients with IBS-D, and the effect was more significant; whether acupuncture is better for IBS-D than it is for constipation or mixed IBS remains to be further studied. A large part of this study included post-2012 studies that were inconsistent in the acupoints selected between IBS-D and other types of IBS, and this study generally included the same acupuncture points to ensure consistency in the assessment of fixed acupuncture points; to yield definitive results, sham acupuncture groups should be increased in further studies.

However, in the past, most studies conducted a direct comparison between acupuncture and pinaverium bromide. There is no direct comparison between acupuncture and other drugs such as ramosetron, alosetron, rifaximin, and eluxadoline. In the future, direct comparisons can be used to compare differences in efficacy. At the same time, this article found that the evaluation scale used in acupuncture-related research is different from other drugs (only 4 points), which will lead to a bias in the evaluation to a certain extent. In the meantime, the quantity of previous acupuncture research is relatively low, so the conclusions remain to be confirmed; these findings can be verified by increasing the sample size and using multicentre double-blind randomized controlled studies.

This study also shows sham acupuncture for the treatment of IBS-D was more effective than other drugs. Previously, there was a lack of direct comparison between sham acupuncture and oral placebo drugs, our study provides an indirect result between sham acupuncture and oral drug placebo, and there exists some curative effect for IBS-D. Actually, sham acupuncture uses the blunt needle as control, which is the same as the mechanisms of acupressure, a previous comment showed sham acupuncture may be not a good control for experiment group \[[@B50]\], and our study has proved this point. Now, there are many studies using sham acupuncture as control group; whether the effect of acupuncture was underestimated still needs direct comparison between sham group and oral placebo. In the future, we need to use the drug placebo control group or improve the sham acupuncture method to weaken the curative effect of sham acupuncture.

This study shows that pinaverium bromide for the treatment of IBS-D was more effective and had fewer side effects than other drugs. Previously, there was a lack of NMA comparing pinaverium bromide and other drugs. A meta-analysis of antispasmodics showed that the pinaverium bromide-induced overall improvement in symptoms of irritable bowel syndrome was 1.55 (CI 95%: 1.33-1.83) and that improvement in abdominal pain was 1.52 (CI%: 1.28-1.80) \[[@B51]\], which is consistent with the results obtained in this study. However, a previous study showed that the efficiency of joint pinaverium bromide-venlafaxine sustained-release tablets on IBS-D reached 85.02%, which was higher than that seen when using only pinaverium bromide (64.29%) \[[@B52]\]. All of the drugs compared in this study were single drugs, and this study was unable to verify multiple drug efficacies.

This study shows that alosetron has better efficacy than ramosetron, but with many side effects. Previous studies have shown the occurrence of side effects from alosetron in the treatment of IBS-D (RR = 1.16, 95% CI: 1.08, 1.25) \[[@B53]\], which is consistent with the results of this study. However, most patients included in our study were female patients with severe IBS-D. Alosetron is not used in the treatment of typical IBS-D patients, but for female patients with severe IBS-D, alosetron may be a good choice.

The most frequently used acupuncture points for IBS-D were ST-25, ST-37, ST-36, SP-6, GV-20, and EX-HN3. Studies have reported that the electrical stimulation of rat hind limbs at ST-36 bits can significantly improve colonic hypersensitivity \[[@B54]\]. Research has shown that using electroacupuncture at the ST25 stimulation site can regulate the brain glucose metabolism rates and improve visceral hypersensitivity \[[@B55]\]. Studies have shown that ST25 and ST37 are able to increase the pain threshold in rats with chronic visceral hypersensitivity by reducing 5-HT concentration and increasing 5-HT4R concentration \[[@B42]\]. Doctors choose the patient\'s acupuncture points based on self-judgement, preferences, and experience. It was very difficult to find consistency in previous studies, which made it difficult to achieve a consistent comparison of results because different acupoints were used. Consistent acupoint studies conducted in the future may be helpful in research or clinical applications.

This study has several advantages and disadvantages. Limitations include the poor quality of some of our studies, the relatively small number of people included, and the fact that some of the studied populations were regional. At the same time, some studies lacked safety records and some results lacked age records, which could have an impact on the results. Meanwhile, the outcome evaluation index used in this study was an overall symptom improvement scale. The drugs used in this study were single drugs. The lack of a combination effect between drugs will have a certain difference from clinical applications.

In summary, this study found that acupuncture may be a good treatment for IBS-D with few side effects, but more research is needed in the future to prove this. Sham acupuncture may be not a good control because of its curative effect for IBS-D. Pinaverium bromide is also a treatment option, as it showed a curative effect with fewer side effects.
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![Identification process for eligible trials.](ECAM2018-2890465.001){#fig1}

![The Forest plot of IBS-D treatment of acupuncture compared with other drugs. A: acupuncture; B: eluxadoline; C: pinaverium bromide; D: alosetron E: ramosetron; F: rifaximin; G: sham acupuncture; H: placebo.](ECAM2018-2890465.002){#fig2}

![The cumulative probability ranking plot of treatment effect of acupuncture and other drugs on IBS-D.](ECAM2018-2890465.003){#fig3}

![The cumulative probability ranking plot of side effect of drugs on IBS-D.](ECAM2018-2890465.004){#fig4}

![The network plot of all treatment methods: yellow means the low-quality studies, green means the high-quality studies.](ECAM2018-2890465.005){#fig5}

![Brooks-Gelman-Rubin diagnostic plot of included studies.](ECAM2018-2890465.006){#fig6}

![Density plot of included studies.](ECAM2018-2890465.007){#fig7}

![Node-splitting plot of included studies.](ECAM2018-2890465.008){#fig8}

![The cumulative contribution plot of IBS-D treatment of acupuncture compared with other drugs. ACU: acupuncture; ELU: eluxadoline; PIN: pinaverium bromide; ALO: alosetron; RAM: ramosetron; RIF: rifaximin; SHAM: sham acupuncture; PLA: placebo.](ECAM2018-2890465.009){#fig9}

![The heterogeneity analysis of included studies. A: acupuncture; B: eluxadoline; C: pinaverium bromide; D: alosetron; E: ramosetron; F: rifaximin; G: sham acupuncture; H: placebo.](ECAM2018-2890465.010){#fig10}

![The funnel plot of all included studies. ACU: acupuncture; ELU: eluxadoline; PIN: pinaverium bromide; ALO: alosetron; RAM: ramosetron; RIF: rifaximin; SHAM: sham acupuncture; PLA: placebo.](ECAM2018-2890465.011){#fig11}

###### 

Characteristics of included studies. NS means no available data.

  Publication Date   Author           Experiment group (n)   Control group (n)   Treatments versus Control                                                               Age of experiment group   Age of control   Diagnosis   Diagnosis criteria   Experiment Events   Control Events   Treatment Duration   Jadad   Gender   Nation          Side Effect€   Side Effect ©   Assessment tool
  ------------------ ---------------- ---------------------- ------------------- --------------------------------------------------------------------------------------- ------------------------- ---------------- ----------- -------------------- ------------------- ---------------- -------------------- ------- -------- --------------- -------------- --------------- -------------------------------------------------------------------------
  2015               LI Xueqing       30                     30                  NS/pinaverium bromide 50mg tid                                                          46±16                     44±16            IBS-D       ROME III             28                  24               8 weeks              2       Mixed    China           0              0               symptom assessment tool (China) (4 points)
  2014               Zhan Daowei      29                     28                  (LR3, ST36,SP6,ST25, ST37,GV20,EX-HN3)*∗*/pinaverium bromide 50mg tid                   42±14                     37±13            IBS-D       ROME III             26                  19               4 weeks              3       Mixed    China           0              0               symptom assessment tool (China) (4 points)
  2014               Kong Suping      29                     28                  (GV20,CV12, ST25, ST36, SP9, ST39)*∗*/pinaverium bromide 50mg tid                       38±11                     38±11            IBS-D       ROME III             26                  23               4 weeks              3       Mixed    China           0              0               symptom assessment tool (China) (4 points)
  2014               Liu Shuying      30                     30                  (GV20,EX-HN3,CV12,ST25,ST37,ST39)*∗*/pinaverium bromide 50mg tid                        41.4±11.8                 41.77±8.99       IBS-D       ROME III             27                  23               4 weeks              1       Mixed    China           0              0               symptom assessment tool (China) (4 points)
  2013               Wu Yuanjian      30                     30                  (ST25, ST36, ST37, SP6, CV8)*∗*/pinaverium bromide 50mg tid                             37.9±10.2                 39.8±11.2        IBS-D       ROME III             26                  24               4 weeks              1       Mixed    China           0              0               symptom assessment tool (China) (4 points)
  2012               Pei Lixia        30                     30                  (ST25, ST36, ST37, SP6, LR3, GV20, EX-HN3)*∗*/pinaverium bromide 50mg tid               40.9±10.6                 37.93±11.45      IBS-D       ROME III             27                  24               4 weeks              3       Mixed    China           0              0               symptom assessment tool (China) (4 points)
  2013               LI HAO           35                     35                  (ST 25, ST 36, ST37, SP6, LR3, GV20, GV29)*∗*/pinaverium bromide 50mg tid               37.9±11.5                 39.1±11.8        IBS-D       ROME III             33                  27               4 weeks              5       Mixed    China           0              0               symptom assessment tool (China) (4 points)
  2011               Sun              30                     30                  (ST 25, ST 36, SP6,LR3,DU20,EX-HN 3 and ST 37)*∗*/pinaverium bromide (50mg tid)         38.81±11.8                38.59±11.45      IBS-D       ROME III             27                  24               4 weeks              3       Mixed    China           0              0               symptom assessment tool (China) (4 points)
  2010               Shi              32                     38                  (ST 25, ST 36, BL 20, BL 21, BL 23, BL 25 and ST 37)*∗*/pinaverium bromide (50mg tid)   38.51±14.65               38.68±15.72      IBS-D       ROME III             26                  20               4 weeks              6       Mixed    China           0              0               Overall IBS symptom VAS score (10 points)
  2017               Lembo (1)        426                    427                 Eluxadoline 100mg /placebo BID                                                          44.4±13.9                 45.8±14.1        IBS-D       ROME III             107                 73               12 weeks             7       Mixed    United States   500/859        450/808         IBS-D global symptom score, Bristol Stool Form Scale
  2017               Lembo (2)        383                    382                 Eluxadoline 100mg /placebo BID                                                          45.7±13.3                 47.1±13.8        IBS-D       ROME III             113                 62               12 weeks             7       Mixed    United States   NS             NS              IBS-D global symptom score, Bristol Stool Form Scale
  2013               DOVE             163                    159                 Eluxadoline 100mg /placebo BID                                                          43.6±10.9                 44.6±12.5        IBS-D       ROME III             46                  22               12 weeks             7       Mixed    United States   73/165         78/159          IBS Global Symptom score, IBS-SSS
  2015               Liang Zheng      218                    209                 Pinaverium 50mg tid/placebo                                                             36.9±11.8                 36.6±12.6        IBS         ROME III             131                 71               4 weeks              7       Mixed    China           40/218         32/209          Bowel Symptom Scale (10 points), Bristol stool form scale
  1977               Levy             30                     30                  Pinaverium 50mg tid/placebo                                                             NS                        NS               IBS         Clinical             24                  17               2 weeks              3       Mixed    French          NS             NS              NS
  1981               Delmont          25                     25                  Pinaverium 50mg tid/placebo                                                             NS                        NS               IBS         Clinical             19                  17               4 weeks              4       Mixed    French          NS             NS              NS
  2005               Lin Chang        131                    128                 Alosetron 1mg/Vitamin C BID                                                             44±12                     43±12            IBS-D       ROME I               69                  51               12 weeks             7       Mixed    United States   86/130         65/128          Average abdominal pain and stool consistency score (5 points)
  2004               William D.Chey   279                    290                 Alosetron 1mg/Vitamin C BID                                                             46.2±13.5                 46.9±12.9        IBS-D       Clinical             144                 119              48 weeks             7       Women    United States   297/348        261/362         Average abdominal pain and stool consistency score (5 points)
  2004               Lembo (1)        147                    135                 Alosetron 2mg/Vitamin C BID                                                             48.9±15.5                 49.4±13.8        IBS-D       Rome II              100                 62               12 weeks             6       Female   United States   145/246        127/246         IBS-D global symptom score, Average stool consistency scores (5 points)
  2004               Lembo (2)        457                    219                 Alosetron 2mg/Vitamin C BID                                                             48.8±14.0                 48.6±13.6        IBS-D       Rome II              320                 99               12 weeks             6       Female   United States   NS             NS              IBS-D global symptom score, Average stool consistency scores (5 points)
  2007               Krause           177                    176                 Alosetron 1mg/Vitamin C BID                                                             43                        43               IBS-D       ROME II              76                  54               12 weeks             7       Women    United States   102/176        94/176          IBS-D global symptom score, Average stool consistency scores (5 points)
  2011               Lee KJ           175                    168                 Ramosetron 5ug Qd/Placebo                                                               43.4±12.1                 45±13.1          IBS-D       Rome III             65                  64               4 weeks              3       Male     Korea           69/147         77/149          IBS symptoms (5 points), Bristol Stool Form Scale
  2008               Matsueda (1)     297                    104                 Ramosetron 1ug Qd, 5ug Qd, 10ug Qd/Placebo                                              40.3±11.8                 38.4±9.56        IBS-D       Rome II              110                 28               12 weeks             6       Mixed    Japan           177/309        61/108          IBS symptoms (5 points), Bristol Stool Form Scale
  2015               Fukudo S AB      307                    102                 Ramosetron 1.25ug Qd, 2.5ug Qd, 5ug Qd/placebo                                          40.9±10.6                 40.2±10.1        IBS-D       Rome III             121                 29               12 weeks             3       Female   Japan           NS             NS              IBS symptoms (5 points), Bristol Stool Form Scale
  2016               Fukudo S         292                    284                 Ramosetron 2.5ug Qd/Placebo                                                             41.4±11.8                 41.5±12.0        IBS-D       Rome III             148                 91               12 weeks             7       Female   Japan           154/292        118/284         IBS symptoms (5 points), Bristol Stool Form Scale
  2008               Matsueda (2)     263                    265                 Ramosetron 5ug Qd/Placebo                                                               40.7±11.21                41.8±11.70       IBS-D       Rome II              124                 72               12 weeks             5       Mixed    Japan           163/270        141/269         IBS symptoms (5 points), Bristol Stool Form Scale
  2014               Fukudo S         147                    149                 Ramosetron 5ug Qd/Placebo                                                               40.9±10.6                 40.2±10.1        IBS-D       Rome III             58                  26               12 weeks             7       Male     Japan           13/175         6/168           IBS symptoms (5 points), Bristol Stool Form Scale
  2008               Lembo            191                    197                 Rifaximin 550mg bid/Placebo                                                             NS                        NS               IBS-D       Rome II              100                 87               2 weeks              4       Mixed    Multicenter     NS             NS              IBS-D global symptom score, IBS-associated bloating
  2011               Primentel (1)    309                    314                 Rifaximin 550mg tid/Placebo                                                             46.2±15.0                 45.5±14.6        Non-C       Rome II              126                 98               2 weeks              7       Mixed    Multicenter     264/624        296/634         IBS symptoms (5 points), Bristol Stool Form Scale
  2011               Primentel (2)    315                    320                 Rifaximin 550mg tid/Placebo                                                             45.9±13.9                 46.3±14.6        Non-C       Rome II              128                 103              2 weeks              7       Mixed    Multicenter     NS             NS              IBS symptoms (5 points), Bristol Stool Form Scale
  2017               Lowe             43                     36                  Acupuncture/sham                                                                        42±15                     43±15            IBS         Rome I               23                  15               4 weeks              7       Mixed    Canada          0              0               IBS Symptoms (5 points), SF-36, IBS-36
  2000               Catherine Lowe   28                     22                  Acupuncture/sham                                                                        NS                        NS               IBS         NS                   16                  10               4 weeks              3       Mixed    Canada          NS             NS              NS
  2009               Anthony J        78                     77                  Acupuncture/sham                                                                        37.5±14.6                 38.9±14.1        IBS         Rome II              32                  24               3 weeks              6       Female   United States   0              0               IBS-Symptom severity scale, IBS-AR, QOL
  2005               Forbes           27                     32                  Acupuncture/sham                                                                        43                        44.4             IBS         Rome+Manning         13                  10               12 weeks             7       Mixed    UK              0              0               global symptom score, Bristol stool scale

###### 

The cumulative probability rankings of treatment effect of acupuncture on IBS-D.

  Methods/Rankings     1              2              3              4              5             6              7             8
  -------------------- -------------- -------------- -------------- -------------- ------------- -------------- ------------- --------------
  Acupuncture          9.774500e-01   0.0221666667   0.0003166667   6.666667e-05   0.000000000   0.0000000000   0.000000000   0.000000e+00
  Eluxadoline          7.000000e-04   0.0183166667   0.1130666667   3.042167e-01   0.260266667   0.2448666667   0.058383333   1.833333e-04
  Pinaverium Bromide   0.000000e+00   0.0371500000   0.6937166667   1.282833e-01   0.070783333   0.0527000000   0.016733333   6.333333e-04
  Alosetron            4.333333e-04   0.0141500000   0.1021333333   3.490500e-01   0.304650000   0.1983666667   0.031200000   1.666667e-05
  Ramosetron           1.333333e-04   0.0056333333   0.0452000000   1.890667e-01   0.312650000   0.3764000000   0.070916667   0.000000e+00
  Rifaximin            1.666667e-05   0.0005333333   0.0039000000   1.546667e-02   0.042683333   0.1198666667   0.806500000   1.103333e-02
  Sham Acupuncture     2.126667e-02   0.9020500000   0.0416666667   1.385000e-02   0.008966667   0.0076833333   0.003983333   5.333333e-04
  Placebo              0.000000e+00   0.0000000000   0.0000000000   0.000000e+00   0.000000000   0.0001166667   0.012283333   9.876000e-01

###### 

The cumulative probability rankings of side effect of drugs on IBS-D.

  Drugs/Possibility   1           2           3          4           5           6
  ------------------- ----------- ----------- ---------- ----------- ----------- -----------
  Eluxadoline         0.0089250   0.0265875   0.082650   0.1953500   0.2967500   0.3897375
  Pinaverium          0.1554125   0.1458000   0.194750   0.1840000   0.1073250   0.2127125
  Alosetron           0.3657750   0.4054750   0.171675   0.0457000   0.0092500   0.0021250
  Ramosetron          0.0335625   0.1281875   0.381825   0.3390875   0.0883750   0.0289625
  Rifaximin           0.4363125   0.2926750   0.149800   0.0673875   0.0296375   0.0241875
  Placebo             0.0000125   0.0012750   0.019300   0.1684750   0.4686625   0.3422750

###### 

Most commonly used acupoints in our included articles.

  Acupoint Number   Frequency   Positions
  ----------------- ----------- -----------
  ST-25             10          Abdomen
  ST-37             9           Leg
  ST-36             8           Leg
  SP-6              5           Leg
  GV20              5           Head
  EX-HN3            4           Forehead

[^1]: Academic Editor: Gioacchino Calapai
